Biomedicines

Journal Browser

► Journal Browser

Special Issue Editors

Dr. Manish Tripathi

E-Mail Website
Guest Editor

1. Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA
2. South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX 78504, USA
Interests: cancer progression; metastasis; lncRNA; transcription regulation; drug resistance; anoikis; CRC; HCC

Dr. Puneet Vij

E-Mail Website
Guest Editor

1. Department of Pharmaceutical Sciences, St. John’s University, Queens, NY 11432, USA
2. Michigan Public Health Institute, Okemos, MI 48842, USA
Interests: colon cancer; cancer biomarkers; resistance; immunotherapy

Special Issue Information

Dear Colleagues,

This Special Issue, “Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy”, aims to provide a comprehensive overview of the advancements made in the field of colorectal cancer prevention and treatment over the past two decades. This Special Issue intends to gather cutting-edge research, review articles, and expert opinions that highlight the significant milestones, breakthroughs, and emerging trends in the management of colorectal cancer.

The scope of this Special Issue includes, but is not limited to, the following topics:

Introduction to colorectal cancer: molecular pathways;
Chemoprevention: mechanisms and effectiveness of various chemopreventive agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and certain dietary components, in reducing the risk of colorectal cancer;
Advances in screening and early detection of colorectal cancer: molecular markers, imaging techniques, and non-invasive tests. liquid biopsy: circulating tumor DNA (ctDNA), microRNAs, and other molecular markers present in blood or other bodily fluids as potential tools for noninvasive monitoring and assessment of colorectal cancer;
Development and clinical application of targeted therapies for colorectal cancer: EGFR inhibitors, VEGF inhibitors, combinatorial therapy, and BRAF inhibitors;
Immunotherapy approaches in colorectal cancer: checkpoint inhibitors, CAR-T cell therapy, and vaccine strategies;
Personalized medicine and precision oncology in colorectal cancer: tailor treatments to individual patients based on their unique characteristics, predictive biomarkers, and the genetic and molecular profile of the tumor. Integration of genomic, transcriptomic, epigenomic, and proteomic data can provide a comprehensive understanding of the tumor;
Emerging therapeutic strategies: combination therapies, immunogenomics, and novel drug targets;
Overcoming resistance to treatment in colorectal cancer: resistance to various therapies can develop, including chemotherapy, targeted therapies, and immunotherapies. Strategies to address resistance in colorectal cancer;
Implementation of colorectal cancer prevention and treatment guidelines: challenges and future directions.

Dr. Manish Tripathi
Dr. Puneet Vij
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

immunotherapy
biomarkers
colorectal cancer
targeted therapies
molecular pathways
resistance
personalized medicine
genomic profiling
chemoprevention

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

22 pages, 3595 KiB

Open AccessArticle

Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer

by Jimmy Stalin, Oriana Coquoz, Rachel Jeitziner Marcone, Stephane Jemelin, Nina Desboeufs, Mauro Delorenzi, Marcel Blot-Chabaud, Beat A. Imhof and Curzio Ruegg

Biomedicines 2023, 11(12), 3185; https://doi.org/10.3390/biomedicines11123185 - 30 Nov 2023

Viewed by 961

Abstract

The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets from human colorectal tumor samples, and applied pharmacological methods in vitro/in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype. Full article

(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)

► Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1208 KiB

Open AccessReview

Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

by Inês Mendes and Nuno Vale

Biomedicines 2024, 12(1), 227; https://doi.org/10.3390/biomedicines12010227 - 19 Jan 2024

Viewed by 1264

Abstract

Gastrointestinal cancers (GICs) are one of the most recurrent diseases in the world. Among all GICs, pancreatic cancer (PC) is one of the deadliest and continues to disrupt people’s lives worldwide. The most frequent pancreatic cancer type is pancreatic ductal adenocarcinoma (PDAC), representing 90 to 95% of all pancreatic malignancies. PC is one of the cancers with the worst prognoses due to its non-specific symptoms that lead to a late diagnosis, but also due to the high resistance it develops to anticancer drugs. Gemcitabine is a standard treatment option for PDAC, however, resistance to this anticancer drug develops very fast. The microbiome was recently classified as a cancer hallmark and has emerged in several studies detailing how it promotes drug resistance. However, this area of study still has seen very little development, and more answers will help in developing personalized medicine. PC is one of the cancers with the highest mortality rates; therefore, it is crucial to explore how the microbiome may mold the response to reference drugs used in PDAC, such as gemcitabine. In this article, we provide a review of what has already been investigated regarding the impact that the microbiome has on the development of PDAC in terms of its effect on the gemcitabine pathway, which may influence the response to gemcitabine. Therapeutic advances in this type of GIC could bring innovative solutions and more effective therapeutic strategies for other types of GIC, such as colorectal cancer (CRC), due to its close relation with the microbiome. Full article

(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)

► Show Figures